Tech Company Financing Transactions

Sudo Biosciences Funding Round

Frazier Healthcare Partners and Velosity Capital participated in a $37 million Series A funding round for Sudo Biosciences. The round was announced on 9/28/2022.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Undisclosed
Menlo Park, CA Undisclosed
USA

Phone

Undisclosed

Website

www.sudobio.com

Email Address

Undisclosed

Overview

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients' lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Scott Byrd

        

Browse more venture capital transactions:

Prev: 9/28/2022: Sitetracker venture capital transaction
Next: 9/28/2022: BioCircuit Technologies venture capital transaction

Share this article

News on VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary